Valuation: Verastem, Inc.

Market Cap 673M 581M 547M 497M 935M 64.47B 948M 6.41B 2.51B 32.24B 2.53B 2.47B 107B P/E 2026 *
-4.63x
P/E 2027 * -6.38x
Enterprise Value 715M 617M 581M 528M 993M 68.49B 1.01B 6.81B 2.67B 34.25B 2.68B 2.63B 114B EV / Sales 2026 *
6.14x
EV / Sales 2027 * 3.71x
Free-Float
99.1%
Yield 2026 *
-
Yield 2027 * -
1 day+3.48%
1 week+5.39%
Current month+28.10%
1 month+23.22%
3 months+74.41%
6 months+30.12%
Current year-3.76%
1 week 6.44
Extreme 6.44
7.68
1 month 5.54
Extreme 5.54
7.68
Current year 3.43
Extreme 3.43
8.88
1 year 3.43
Extreme 3.43
11.24
3 years 2.1
Extreme 2.1
14.22
5 years 2.1
Extreme 2.1
42.96
10 years 2.1
Extreme 2.1
124.2
Manager TitleAgeSince
Chief Executive Officer 65 01/08/2023
Director of Finance/CFO 39 31/10/2022
Chief Tech/Sci/R&D Officer - 18/04/2024
Director TitleAgeSince
Chairman 62 -
Director/Board Member 65 01/08/2023
Director/Board Member 69 03/05/2017
Date Insider Type Main position Quantity % Market Cap.
3/8/26 Sell

Chief Executive Officer

-1,302 0.0021%
21/5/26 Free

Director

36,000 0.0410%
21/5/26 Free

Director

36,000 0.0410%
Change 5-day change 1-year change 3-year change Capi.($)
+3.48%+5.39%-6.78%-27.51% 673M
+0.17%+4.35%+72.39%+114.97% 73.45B
+0.57%+14.98%+56.53%+91.84% 62.99B
+0.11%-3.10%+0.94%+491.16% 28.05B
-1.40%+4.81%+60.85%+20.35% 25.42B
+1.26%-0.05%-17.59%-15.96% 23.3B
+1.00%+4.07%+39.89%-15.03% 19.45B
-0.71%-4.11%+243.99%+423.83% 18.16B
-3.50%-0.95%+14.80%+515.88% 16.53B
+1.53%+3.49%+40.68%+151.75% 13.16B
Average +0.25%+3.81%+50.57%+175.13% 28.12B
Weighted average by Cap. +0.06%+5.69%+56.99%+163.83%

Financials

2026 *2027 *
Net sales 116M 101M 94.63M 86M 162M 11.16B 164M 1.11B 435M 5.58B 437M 428M 18.59B 181M 156M 147M 134M 252M 17.35B 255M 1.73B 677M 8.68B 680M 665M 28.91B
Net income -166M -143M -135M -123M -230M -15.89B -234M -1.58B -620M -7.95B -623M -609M -26.48B -157M -136M -128M -116M -218M -15.05B -221M -1.5B -587M -7.53B -590M -577M -25.07B
Net Debt 41.9M 36.19M 34.05M 30.95M 58.2M 4.01B 59.06M 399M 157M 2.01B 157M 154M 6.69B -
Logo Verastem, Inc.
Verastem, Inc. is a late-stage development biopharmaceutical company, which focuses on the development and commercialization of new medicines to improve the lives of patients diagnosed with ras sarcoma (RAS)/ mitogen-activated pathway kinase (MAPK) pathway-driven cancers. Its product candidates include avutometinib and defactinib. Avutometinib is an oral RAF/MEK clamp that inhibits MEK1/2 kinase activities and induces inactive complexes of MEK with A-Raf proto-oncogene, potentially serine/threonine kinase (ARAF), B-Raf proto-oncogene serine/threonine kinase (BRAF) and C-raf proto-oncogene serine/threonine kinase, creating antitumor response through maximal RAS/MAPK pathway inhibition. Defactinib is an oral, selective inhibitor of FAK and proline-rich tyrosine kinase (PYK2), the two members of the focal adhesion kinase family of non-receptor protein tyrosine kinases. FAK and PYK2 integrate signals from integrin and growth factor receptors to regulate cell proliferation.
Employees
102
Date Price Change Volume
18/08/26 USD 7.430 +3.48% 2,924,317
17/08/26 USD 7.180 +9.12% 2,284,012
14/08/26 USD 6.580 -1.35% 1,280,177
13/08/26 USD 6.670 -4.03% 1,856,897
12/08/26 USD 6.950 -1.42% 1,263,817
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
7.430USD
Average target price
14.75USD
Spread / Average Target
+98.52%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. VSTM Stock